AU2006343402A1 - Methods for the treatment of muscular dystrophy associated with dysferlin-deficiency - Google Patents

Methods for the treatment of muscular dystrophy associated with dysferlin-deficiency Download PDF

Info

Publication number
AU2006343402A1
AU2006343402A1 AU2006343402A AU2006343402A AU2006343402A1 AU 2006343402 A1 AU2006343402 A1 AU 2006343402A1 AU 2006343402 A AU2006343402 A AU 2006343402A AU 2006343402 A AU2006343402 A AU 2006343402A AU 2006343402 A1 AU2006343402 A1 AU 2006343402A1
Authority
AU
Australia
Prior art keywords
antibody
mammal
dysferlin
complement
antibodies
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2006343402A
Other languages
English (en)
Inventor
Russell Rother
Simone Spuler
Katrin Wenzel
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alexion Pharmaceuticals Inc
Original Assignee
Alexion Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alexion Pharmaceuticals Inc filed Critical Alexion Pharmaceuticals Inc
Publication of AU2006343402A1 publication Critical patent/AU2006343402A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Neurology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
AU2006343402A 2006-05-01 2006-05-01 Methods for the treatment of muscular dystrophy associated with dysferlin-deficiency Abandoned AU2006343402A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2006/016980 WO2007130031A1 (fr) 2006-05-01 2006-05-01 Procedes de traitement de la dystrophie musculaire associee a une deficience en dysferline

Publications (1)

Publication Number Publication Date
AU2006343402A1 true AU2006343402A1 (en) 2007-11-15

Family

ID=37866247

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2006343402A Abandoned AU2006343402A1 (en) 2006-05-01 2006-05-01 Methods for the treatment of muscular dystrophy associated with dysferlin-deficiency

Country Status (4)

Country Link
EP (1) EP2013235A1 (fr)
AU (1) AU2006343402A1 (fr)
CA (1) CA2650718A1 (fr)
WO (1) WO2007130031A1 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2965283T3 (es) 2006-03-15 2024-05-28 Alexion Pharma Inc Tratamiento de pacientes con hemoglobinuria paroxística nocturna mediante un inhibidor del complemento
WO2008048689A2 (fr) * 2006-10-20 2008-04-24 Alexion Pharmaceuticals, Inc. Méthodes de traitement d'une dystrophie musculaire associée à une carence en dysferline
US9447176B2 (en) * 2008-11-10 2016-09-20 Alexion Pharmaceuticals, Inc. Methods and compositions for treating complement-associated disorders

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6074642A (en) * 1994-05-02 2000-06-13 Alexion Pharmaceuticals, Inc. Use of antibodies specific to human complement component C5 for the treatment of glomerulonephritis

Also Published As

Publication number Publication date
WO2007130031A1 (fr) 2007-11-15
EP2013235A1 (fr) 2009-01-14
CA2650718A1 (fr) 2007-11-15

Similar Documents

Publication Publication Date Title
US10703809B1 (en) Treatment of paroxysmal nocturnal hemoglobinuria patients by an inhibitor of complement
US20230114726A1 (en) Methods and compositions for treatment of amyloid deposition diseases
BRPI0619357B1 (pt) Anticorpos monoclonais, composição farmacêutica, vacina, uso dos mesmos para tratamento ou prevenção de doença de alzheimer, métodos in vitro para diagnosticar e para identificar compostos apropriados para imunização de doença de alzheimer e kits
WO2011151076A2 (fr) Anticorps monoclonaux ciblant des oligomères aβ
EP3345619A1 (fr) Anticorps humains et leurs utilisations diagnostiques et thérapeutiques pour le traitement de maladies neurologiques
US11136383B2 (en) Methods and compositions for modulaton of transforming growth factor beta-regulated functions
US20090041764A1 (en) Methods for the treatment of muscular dystrophy associated with dysferlin-deficiency
WO2007130031A1 (fr) Procedes de traitement de la dystrophie musculaire associee a une deficience en dysferline
BR112016027671B1 (pt) Uso de um anticorpo
JP2019210290A (ja) 代謝性疾患を処置する方法
CN117561078A (zh) 用于评价发展急性covid-19和急性后covid-19的风险的生物标志物
HK1232786A1 (en) Treatment of paroxysmal nocturnal hemoglobinuria patients by an inhibitor of complement
HK1235319B (en) Treatment of paroxysmal nocturnal hemoglobinuria patients by an inhibitor of complement
HK1188731B (en) Human antibodies and diagnostic and therapeutic uses thereof for the treatment of neurological disease
HK1188731A (en) Human antibodies and diagnostic and therapeutic uses thereof for the treatment of neurological disease

Legal Events

Date Code Title Description
MK1 Application lapsed section 142(2)(a) - no request for examination in relevant period